Drugs / Faringel plus
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04911335 | Jul 2021 → Nov 2022 | mucositis | Campus-Bio-Medico University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Faringel plus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04911335 ↗ |
| Route | Oral | “Each administration will contain 7 ml of oral suspension” NCT04911335 ↗ |